CLINICAL TRIALS PROFILE FOR TRODUSQUEMINE

Clinical Trials for Trodusquemine

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00509132 ↗	A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers	Completed	Genaera Corporation	Phase 1	The purpose of this study is to evaluate the safety and tolerance of single intravenous (through a vein) doses of trodusquemine. Different amounts of trodusquemine will be given to each volunteer group throughout the study. Another purpose is to evaluate the pharmacokinetics (PK - the study of the way the drug enters and leaves the blood and tissues over time) of trodusquemine. Finally, this study will also determine whether trodusquemine has any effect on appetite, mood or behavior, and selective biomarkers (substances in your blood that may change in response to the study drug).
NCT00606112 ↗	A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers	Completed	Genaera Corporation	Phase 1	The purpose of this study is to evaluate the safety and tolerance of a single intravenous (through a vein) dose of trodusquemine (MSI-1436) in obese, type 2 diabetics. Different amounts of trodusquemine (MSI-1436) will be given to each volunteer group throughout the study. Another purpose is to evaluate the pharmacokinetics (PK - the study of the way the drug enters and leaves the blood and tissues over time) of trodusquemine (MSI-1436). Finally, this study will also determine whether trodusquemine (MSI-1436) has any effect on appetite, mood or behavior, and selective biomarkers (substances in your blood that may change in response to the study drug).
NCT00806338 ↗	An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers	Completed	Genaera Corporation	Phase 1	The purpose of this study is to evaluate the safety and tolerance of multiple intravenous (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics.
NCT02524951 ↗	Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer	Terminated	DepYmed Inc.	Phase 1	This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
NCT02524951 ↗	Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer	Terminated	Northwell Health	Phase 1	This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a single intravenous infusion twice a week for 3 weeks on a 4-week cycle.

Clinical Trial Conditions for Trodusquemine

Condition Name

Condition Name
Intervention	Trials
Obesity	3
Diabetes Mellitus	2
Metastatic Breast Cancer	1

Condition MeSH

Condition MeSH
Intervention	Trials
Diabetes Mellitus	2
Breast Neoplasms	1
Overweight	1

Clinical Trial Locations for Trodusquemine

Trials by Country

Trials by Country
Location	Trials
United States	5

Trials by US State

Trials by US State
Location	Trials
Texas	2
New York	1
Florida	1
Kansas	1

Clinical Trial Progress for Trodusquemine

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 1	4

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	3
Terminated	1

Clinical Trial Sponsors for Trodusquemine

Sponsor Name

Sponsor Name
Sponsor	Trials
Genaera Corporation	3
DepYmed Inc.	1
Northwell Health	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	4
Other	1